Liberum Capital restated their buy rating on shares of AstraZeneca plc (LON:AZN) in a research report released on Thursday. Liberum Capital currently has a GBX 5,100 ($62.35) price target on the biopharmaceutical company’s stock. AZN has been the topic of several other reports. Credit Suisse Group AG restated an underperform rating and set a GBX […]
